In a groundbreaking development, Strand Therapeutics has revealed the initial Phase 1 data for STX-001 in patients with advanced solid tumors. This mRNA therapeutic aims to address the urgent need for new treatment options in patients who are resistant to immune checkpoint inhibitors. By delivering localized IL-12 expression to activate the tumor microenvironment and stimulate […]